WeightControl.com: What are the main findings?
Response: Use went from almost zero to a sharp rise in just a few years. Today, about 1.1% of new Danish mothers start Wegovy within six months after birth — roughly 650 women a year. Most were already overweight before pregnancy, and only a minority had diabetes, so the main purpose was weight loss.
WeightControl.com: What should readers take away from your report?
Response: The big message is speed: The uptake has surged, but the knowledge hasn’t caught up. The postpartum period is a time of major hormonal shifts, natural weight loss, and breastfeeding — and we still don’t fully know how these medications interact with that. Semaglutide does not seem to appear in breast milk, which is reassuring, but many other questions remain.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: We urgently need studies that look at postpartum physiology, breastfeeding, milk production, and milk composition. Even small changes could matter for infants. We also need real-world safety data so clinicians can give clear, confident guidance.
WeightControl.com: Is there anything else you would like to add? Any disclosures?
Response: This shift has happened incredibly fast, and many clinicians may not realize how common postpartum GLP-1 use has already become. Better evidence is essential to support women during a vulnerable time.
Dr. Pottegård reports receiving grants form Alcon, Almirall, AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, LEO Pharma, and Astrellas outside the submitted work. The other authors have nothing to report.
Citation:
Bliddal M, Nohmie G, Damkier P, Pottegård A. Increasing Postpartum Use of GLP-1 Receptor Agonists. JAMA. Published online November 24, 2025. doi:10.1001/jama.2025.20947
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 24, 2025 by weightcontrol